Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

315.28 +9.91 (+3.25%)
Streaming Delayed Price Updated: 2:34 PM EDT, Jun 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Praxis Precision Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Provides Vormatrigine Program Update
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA 
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor
Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026 
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.